Dataset Information

MiRNA expression data in plasma from women with breast cancer and healthy volunteers with or without alterations associated to metabolic syndrome [array]

ABSTRACT: Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Early diagnosis is improving the survival of BCa patients but more sensitive and specific tools are still necessary. We propose the use of miRNAs as a biomarker alternative in BCa diagnosis. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Furthermore, metabolic syndrome (MeS) is a risk factor for BCa. Molecular mechanisms underlaying this association have not been fully elucidated. The aim of this work was to identify the circulating miRNAs in plasma of BCa patients and healthy donors with or without clinical features linked to MeS. MiRNAs were isolated from plasma of woman. BCa patients (N=30) were distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. Healthy women (HD) (N=36) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). miRNA expression profile was also determined by miRNA sequencing from 6 BC patients and 4 HD. Data analysis revealed 11 miRNAs upregulated in the plasma from BCa patients compared to HD. Meanwhile, 24 miRNAs were altered in plasma of women with MeSL compared to control.

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE235353 | GEO | 2024/08/31

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:BACKGROUND MicroRNAs (miRNAs) are small non-coding RNAs that recognize sites of complementarity of target messenger RNAs, resulting in transcriptional regulation and translational repression of target genes. In Huntington’s disease (HD), a neurodegenerative disease caused by a trinucleotide repeat expansion, miRNA dyregulation has been reported, which may impact gene expression and modify the progression and severity of HD. METHODS: We performed next-generation miRNA sequence analysis in prefrontal cortex (Brodmann Area 9) from 26 HD, 2 asymptomatic HD, and 36 control brains. Neuropathological information was available for all HD brains, including age at disease onset, CAG-repeat size, Vonsattel grade, and Hadzi-Vonsattel striatal and cortical scores, a continuous measure of the extent of neurodegeneration. Linear models were performed to examine the relationship of miRNA expression to these clinical features, and messenger RNA targets of associated miRNAs were tested for gene ontology term enrichment. RESULTS: We identified 75 miRNAs differentially expressed in HD brain (FDR q-value <0.05). Among the HD brains, nine miRNAs were significantly associated with Vonsattel grade of neuropathological involvement and three of these, miR-10b-5p, miR-10b-3p, and miR-302a-3p, significantly related to the Hadzi-Vonsattel striatal score (a continuous measure of striatal involvement) after adjustment for CAG length. Five miRNAs (miR-10b-5p, miR-196a-5p, miR-196b-5p, miR-10b-3p, and miR-106a-5p) were identified as having a significant relationship to CAG length-adjusted age of onset including miR-10b-5p, the mostly strongly over-expressed miRNA in HD cases. Although prefrontal cortex was the source of tissue profiled in these studies, the relationship of miR-10b-5p expression to striatal involvement in the disease was independent of cortical involvement. Correlation of miRNAs to the clinical features clustered by direction of effect and the gene targets of the observed miRNAs showed association to processes relating to nervous system development and transcriptional regulation. CONCLUSIONS: These results demonstrate that miRNA expression in cortical BA9 provides insight into striatal involvement and support a role for these miRNAs, particularly miR-10b-5p, in HD pathogenicity. The miRNAs identified in our studies of postmortem brain tissue may be detectable in peripheral fluids and thus warrant consideration as accessible biomarkers for disease stage, rate of progression, and other important clinical characteristics of HD. 26 Huntington's disease, 2 asymptomatic HD gene positive and 49 neurologically normal control prefrontal cortex samples

Project description:PURPOSE: To investigate the circulatory microRNA (miRNA) profiles of aqueous, vitreous, and plasma in order to identify biomarkers in aqueous humor or plasma that are reflecting changes in vitreous of patients with diabetes. METHODS: Aqueous, vitreous and plasma samples were collected from a total of 27 patients - 11 controls (macular pucker or macular hole patients) and 16 patients with diabetes mellitus (DM) undergoing vitreoretinal surgery: DM-Type I with proliferative diabetic retinopathy (PDR) (DMI-PDR), DM Type II with PDR (DMII-PDR) and DM Type II with nonproliferative DR (DMII-NPDR). MiRNAs were isolated using Qiagen microRNeasy kit, quantified on BioAnalyzer, labeled with FlashTag kit, and profiled on Affymetrix GeneChip miRNA 3.0 microarrays. Data analysis was done using Expression Console (EC), Transcriptome Analysis Console (TAC), and Ingenuity Pathway Analysis (IPA) software. RESULTS: Our comparison of circulatory miRNA population of aqueous and vitreous humor and plasma showed that out of total of 847 human miRNA probes on the Affymetrix GeneChip miRNA 3.0 we found common miRNAs for both aqueous and vitreous samples, as well as larger number of unique miRNA, dependent on the DM type and presence of retinopathy. Most of the dysregulated miRNAs in aqueous and vitreous of DM patients were upregulated, while in plasma, most of the DM-specific miRNAs were downregulated. Dysregulation of miRNAs in aqueous generally do not appear to be a good representative of the miRNA abundance in vitreous, or plasma, although we did identify a few candidates for common biomarkers: let-7b, miR-320b, miR-762 and miR-4488. Additionally, each of the DR subtypes showed a set of miRNA that is uniquely dysregulated in each fluid, for example in aqueous samples for DMII-NPDR it was miR-455-3p, for DMII-PDR was miR-296, and for DMI-PDR it was miR-3202. Pathway analysis identified TGF-beta and VEGF pathways as the common targets for miRNAs dysregulated in DR aqueous and vitreous. CONCLUSIONS: The comparative profiling of circulatory miRNAs in aqueous, vitreous, and plasma showed that a small number of circulatory miRNAs displayed differential presence in controls vs. diabetic retinopathy. A pattern is emerging of sets of miRNA that are common or uniquely dysregulated in the blood plasma or ocular fluids of DR subtypes, offering promise for the use of ocular fluids and plasma for identifying diagnostic and therapeutic targets.

Dataset Information

MiRNA expression data in plasma from women with breast cancer and healthy volunteers with or without alterations associated to metabolic syndrome [array]

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure